Nine years after ranibizumab or laser for ROP, vision and refraction were similar

The edition in brief

In a single-centre trial that randomised 50 infants with zone II ROP to ranibizumab or laser in 2014, 29 children were examined at nine years. Mean spherical equivalent (−1.90 vs −1.22 D) and visual acuity (0.21 vs 0.15 logMAR) did not differ significantly; ranibizumab-treated eyes had thinner lenses, steeper corneas and thinner central retinas. Loss to follow-up was large and uneven. In a central Indian tertiary centre, reliable 30-2 visual fields were abnormal in 58% of neurological referrals, and confirmed neurological disease in 52%, against 2% of other referrals. The FDA lists a supplement to a generic acetazolamide application, an administrative action. In UK primary care data on 218,056 men with glaucoma and 876,872 controls, prescribed erectile dysfunction medication was associated with slightly higher glaucoma risk (OR 1.17 to 1.29). In the phase 3 LYNX-1 trial, phentolamine 0.75% drops improved mesopic low-contrast acuity in 21% versus 3% on placebo at day 15.